Korea paints too rosy picture for biosimilars development

The government is now being criticized for only drawing a “hollow’’ picture on the biosimilars sector, since there are many key challenges and huddles.

Critics and industry sources said the government’s optimistic approach on biosimilars should be restrained in consideration of negative factors, adding biosimilar development is riddled with complexities, ranging from regulatory, to manufactu...